Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Thalidomide (Thalidomide Celgene) - Important Safety Information from Celgene Ltd. as approved by the HPRA
Notice type:
3rd Party Publications
Date:
12/11/2015
Problem Or Issue:
Important Safety Information communication from Celgene Ltd. on the starting dose of Thalidomide (Thalidomide Celgene) when combined with melphalan should be reduced in patients over 75 years.
Important Safety Information - Thalidomide (Thalidomide Celgene)
« Back
Date Printed: 19/04/2024